Vivek Ramaswamy Wins Republican Primary for Ohio Governor
Vivek Ramaswamy secured the Republican nomination for governor of Ohio in Tuesday's primary election. The biotech executive turned politician defeated other contenders to become his party's candidate. Ramaswamy now faces a general election where betting markets give him a 47 percent chance of victory against the Democratic nominee.
BBC NewsVivek Ramaswamy won the Republican primary for governor of Ohio on Tuesday, according to multiple outlets reporting the election results. The victory positions the biotech executive-turned-politician as the GOP nominee in a race that has drawn national attention as one of several closely watched contests in the Midwest.
Ramaswamy emerged victorious after a competitive primary battle. Betting markets currently give him a 47 percent chance of winning the general election, with the Democratic candidate in the lead, according to Kalshi.
Ramaswamy's win was confirmed across several news organizations covering the Ohio primary elections held Tuesday. The outcome advances his bid to become the state's next governor. The primary also featured a Senate contest in which Sherrod Brown secured the Democratic nomination as he seeks a return to the upper chamber.
Both races were part of a series of key Midwest primaries. Ramaswamy, who has been described as a staunch Trump ally, prevailed in the Republican gubernatorial field. His background includes experience as a biotech executive before entering politics.
Prediction markets indicate the general election remains competitive. One platform assessed Ramaswamy's odds of victory at 47 percent as of Wednesday morning. The race pits the Republican nominee against the Democratic candidate in what could prove a closely contested general election in the battleground state.
In other developments reported the same day, German drug maker Bayer said it is acquiring Perfusion Therapeutics, a privately held developer of treatments for eye diseases. Madrigal Pharma reported first-quarter sales of its MASH drug Rezdiffra reached $311 million, exceeding Wall Street estimates.
United Therapeutics also released its earnings results. Novo Nordisk saw its shares rise after reporting first-quarter results and raising its full-year guidance. " — STAT, May 6, 2026 CellCentric raised $220 million to advance its myeloma drug candidate, part of ongoing financing activity in the biotech sector.
Transparency
Clean fact-forward rewrite with minimal inherited framing; betting-market odds and neutral descriptors dominate without loaded verbs or lede misdirection.
Valence skew: subtly frames Ramaswamy as underdog via betting odds
Ramaswamy, a biotech entrepreneur and former presidential candidate, secured a decisive Republican nomination for Ohio governor, demonstrating strong primary voter support for his outsider profile.
4 independent outlets report the same core facts. This score blends how many outlets corroborate, their editorial tier, and how closely their facts agree — it measures corroboration, not proof.
Sources framed at 55 → our rewrite 18. We stripped 37 points of framing the sources carried in.
Story details
Related Stories
Fox NewsJustice Department Abandons $1.8 Billion Anti-Weaponization Fund
Acting Attorney General Todd Blanche told Congress the department will not proceed with the fund. A separate agreement shielding President Donald Trump and his businesses from past IRS claims remains in place.
**Trump Administration Scraps $1.8 Billion Compensation Fund**
The Justice Department will not create a planned $1.8 billion fund intended to compensate people who say they were improperly targeted by federal law enforcement. Acting Attorney General Todd Blanche told lawmakers the department is abandoning the program entirely.
The HillPentagon Appoints Elias Irizarry, Who Participated in January 6 Capitol Riot at Age 19, to Special Operations Office
Elias Irizarry, who pleaded guilty to entering a restricted building during the January 6, 2021, Capitol events, has been named to a position in the Office of Special Operations and Low Intensity Conflict.